In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Myriad gets exclusive ex-US rights to sell Sividon's EndoPredict prognostic

Executive Summary

Sividon Diagnostics GMBH granted Myriad Genetics GMBH exclusive rights to co-promote the EndoPredict cancer prognosis test outside of the US. The deal has an intial three-year term, and is renewable for two additional years.

Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies